More than 2.3 million cases of non-melanoma skin cancer occur each year in the United States. Cutaneous squamous cell carcinoma forms a major share of that total. Lifetime risk reaches 7 percent for men and 3 percent for women in high-income populations.
Key Takeaways
- Risk of developing squamous cell carcinoma increases with immunosuppression; organ transplant recipients have a markedly higher risk of non-melanoma skin cancer.
- In the U.S., the 5-year relative survival for cervical cancer is 66% (SEER; invasive cervical cancer).
- The cumulative lifetime probability of developing squamous cell carcinoma of the skin is 7% for men and 3% for women in high-income populations (global estimates; used in risk framing for cutaneous SCC).
- For oral cavity and pharynx cancers, SEER shows 32% diagnosed at distant stage (all histologies; SCC dominant but not isolated).
- 75% of cutaneous squamous cell carcinomas occur on the head and neck region (site distribution for keratinocyte carcinomas).
- Smoking increases the risk of head and neck squamous cell carcinoma; current smokers have a higher risk than never-smokers (dose and duration matter; meta-analytic summary).
- For vulvar cancer, 5-year relative survival is about 86% for localized disease and about 54% for regional disease in SEER (SCC predominantly).
- Cervical cancer is associated with HPV in about 90% of cases (WHO).
- For low-risk primary cutaneous SCC treated with standard excision, 5-year recurrence can be higher than Mohs; comparative cohort evidence reports recurrence differences (study context).
- In the U.S., melanoma incidence increased from 2013 to 2022 by 13.2% (while non-melanoma skin cancers remain the larger burden), highlighting that cutaneous SCC is a major share of the non-melanoma cancer pool
- Cemiplimab achieved an objective response rate (ORR) of 47% in advanced cutaneous squamous cell carcinoma in a pivotal trial (with durable responses reported)
- Nivolumab in metastatic or recurrent head and neck squamous cell carcinoma demonstrated 1-year survival of 36% (vs 16% with investigator’s choice) in CheckMate 141
- KEYNOTE-048 reported grade ≥3 treatment-emergent adverse events occurring in about 85% of patients receiving pembrolizumab plus chemotherapy
- Alcohol consumption is associated with increased risk of head and neck squamous cell carcinoma in meta-analysis (higher intake levels show higher risk vs lower/no intake)
- Radiotherapy for head and neck cancer increases the risk of subsequent radiation-induced malignancies in irradiated fields (evidence from long-term follow-up studies)
Immunosuppression raises squamous cell carcinoma risk, and outcomes vary widely by stage, site, and treatment.
Related reading
01 · Category
Incidence & Burden4 stats
01
Risk of developing squamous cell carcinoma increases with immunosuppression; organ transplant recipients have a markedly higher risk of non-melanoma skin cancer.
02
In the U.S., the 5-year relative survival for cervical cancer is 66% (SEER; invasive cervical cancer).
03
The cumulative lifetime probability of developing squamous cell carcinoma of the skin is 7% for men and 3% for women in high-income populations (global estimates; used in risk framing for cutaneous SCC).
04
2.3 million new cases of skin cancer (non-melanoma including squamous cell carcinoma) occur in the U.S. annually (American Academy of Dermatology; includes SCC).
Interpretation
Incidence & Burden Interpretation
For incidence and burden, squamous cell carcinoma represents a sizable and growing skin cancer load with 2.3 million annual skin cancer cases in the U.S. and a lifetime risk estimated at 7% in men and 3% in women in high-income populations.
02 · Category
Epidemiology & Risk Factors10 stats
01
For oral cavity and pharynx cancers, SEER shows 32% diagnosed at distant stage (all histologies; SCC dominant but not isolated).
02
75% of cutaneous squamous cell carcinomas occur on the head and neck region (site distribution for keratinocyte carcinomas).
03
Smoking increases the risk of head and neck squamous cell carcinoma; current smokers have a higher risk than never-smokers (dose and duration matter; meta-analytic summary).
04
Alcohol consumption is associated with increased risk of head and neck squamous cell carcinoma (risk increases with higher intake; meta-analysis).
05
Radiation (including ionizing radiation exposure) increases risk for squamous cell skin cancers in irradiated fields (radiation as a causal risk factor).
06
Chronic inflammation and scars (Marjolin-type risk) are known risk factors for developing cutaneous squamous cell carcinoma arising in scar tissue or chronic wounds.
07
In the U.S., 52% of cancers are diagnosed at a localized stage (overall SEER; contextual benchmark relevant to skin SCC and other SCC sites).
08
For cutaneous squamous cell carcinoma, the risk of recurrence increases with tumor size, depth of invasion, perineural invasion, and poor differentiation (validated clinicopathologic risk factors).
09
Presence of perineural invasion is a strong adverse prognostic factor in cutaneous squamous cell carcinoma (systematic evidence summary).
10
Poorly differentiated cutaneous SCC is associated with higher metastasis and recurrence risk (correlated in clinical cohorts).
Interpretation
Epidemiology & Risk Factors Interpretation
Across epidemiology and risk factors, the strongest takeaway is that while 75% of cutaneous squamous cell carcinomas arise on the head and neck and smoking plus alcohol meaningfully raise head and neck SCC risk, prognosis worsens in cutaneous disease as clinicopathologic features like larger size, deeper invasion, perineural invasion, and poor differentiation drive higher recurrence and metastasis risk.
03 · Category
Treatment & Outcomes17 stats
01
For vulvar cancer, 5-year relative survival is about 86% for localized disease and about 54% for regional disease in SEER (SCC predominantly).
02
Cervical cancer is associated with HPV in about 90% of cases (WHO).
03
For low-risk primary cutaneous SCC treated with standard excision, 5-year recurrence can be higher than Mohs; comparative cohort evidence reports recurrence differences (study context).
04
Mohs micrographic surgery yields higher cure rates than standard excision for high-risk cutaneous squamous cell carcinoma (comparative evidence; cure rates in meta-analyses).
05
Radiotherapy is an established definitive option for cutaneous squamous cell carcinoma when surgery is not feasible; local control rates are reported in clinical series (range varies by dose and risk).
06
For patients with localized head and neck squamous cell carcinoma treated with radiotherapy alone, 2-year overall survival is reported in clinical studies around 60% (varies by subsite and regimen).
07
Cetuximab plus chemotherapy improved overall survival vs chemotherapy alone in recurrent/metastatic HNSCC by about 2.7 months (EXTREME; median 10.1 vs 7.4).
08
In KEYNOTE-048, grade ≥3 adverse events occurred in about 85% of patients receiving pembrolizumab plus chemotherapy (safety reporting).
09
In CheckMate 141, 1-year survival was about 36% with nivolumab vs about 16% with investigator’s choice (trial survival timepoint).
10
In the JAVELIN Head and Neck 100 trial, avelumab did not improve overall survival vs standard chemotherapy in recurrent/metastatic HNSCC (median OS difference; trial reporting).
11
The phase 2 trial of pembrolizumab for advanced cutaneous squamous cell carcinoma is ongoing/has reported efficacy signals in multiple cohorts; however, the most definitive ORR figure is cemiplimab 47% (pivotal NEJM trial).
12
In KEYNOTE-158, the overall response rate was 14.3% for pembrolizumab in previously treated metastatic cervical cancer (which is predominantly squamous histology in many regions).
13
In cervical cancer, VEGF inhibition with bevacizumab increases median overall survival by 3.0 months compared with chemotherapy alone in GOG-0240 (recurrent/persistent).
14
For locally advanced cervical cancer, standard chemoradiotherapy yields 5-year survival around 60% (benchmark in cervical cancer treatment literature; depends on stage).
15
In anal cancer, chemoradiation is standard and yields high cure rates; 5-year overall survival around 70% is reported in mature cohorts (varies by risk).
16
In a classic randomized trial for advanced vulvar cancer, complete response rates with cisplatin-based chemoradiation approaches were reported around 60% (depends on study).
17
In the Phase 3 Javelin Bladder 100 trial, avelumab did not translate to survival benefit in its setting; for HNSCC, JAVELIN Head and Neck 100 reported no OS benefit (context for immunotherapy performance).
Interpretation
Treatment & Outcomes Interpretation
Across treatment choices in Squamous Cell Carcinoma, outcomes consistently favor therapies that improve local control and survival, with key examples including 5-year localized vulvar survival at about 86% versus 54% for regional disease and, in recurrent or metastatic head and neck SCC, cetuximab plus chemotherapy extending median overall survival from 7.4 to 10.1 months.
04 · Category
Epidemiology1 stats
01
In the U.S., melanoma incidence increased from 2013 to 2022 by 13.2% (while non-melanoma skin cancers remain the larger burden), highlighting that cutaneous SCC is a major share of the non-melanoma cancer pool
Interpretation
Epidemiology Interpretation
In U.S. epidemiology, melanoma incidence rose by 13.2% from 2013 to 2022, underscoring that cutaneous squamous cell carcinoma remains a major contributor within the larger non-melanoma skin cancer burden.
More related reading
05 · Category
Clinical Outcomes5 stats
01
Cemiplimab achieved an objective response rate (ORR) of 47% in advanced cutaneous squamous cell carcinoma in a pivotal trial (with durable responses reported)
02
Nivolumab in metastatic or recurrent head and neck squamous cell carcinoma demonstrated 1-year survival of 36% (vs 16% with investigator’s choice) in CheckMate 141
03
KEYNOTE-048 reported grade ≥3 treatment-emergent adverse events occurring in about 85% of patients receiving pembrolizumab plus chemotherapy
04
In the GOG-0240 trial, median overall survival was 17.0 months with bevacizumab plus chemotherapy vs 14.9 months with chemotherapy alone (improved by ~3 months)
05
In the phase 3 JAVELIN Head and Neck 100 trial, avelumab did not improve overall survival compared with investigator’s choice chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma
Interpretation
Clinical Outcomes Interpretation
Across these clinical outcomes, immunotherapy and targeted approaches show meaningful response or survival signals in specific settings, with cemiplimab delivering a 47% ORR and nivolumab improving 1-year survival to 36% versus 16%, while other strategies like avelumab in JAVELIN Head and Neck 100 and the modest 3-month overall survival gain in GOG-0240 underscore that benefits are not consistent across all squamous cell carcinoma subtypes.
06 · Category
Risk Factors5 stats
01
Alcohol consumption is associated with increased risk of head and neck squamous cell carcinoma in meta-analysis (higher intake levels show higher risk vs lower/no intake)
02
Radiotherapy for head and neck cancer increases the risk of subsequent radiation-induced malignancies in irradiated fields (evidence from long-term follow-up studies)
03
Organ transplant recipients have higher incidence of non-melanoma skin cancer than the general population (evidence summarized in large cohort studies)
04
Chronic inflammation and scars are associated with an increased risk of developing cutaneous squamous cell carcinoma arising in scar tissue (Marjolin-type carcinogenesis described in clinical literature)
05
In cutaneous squamous cell carcinoma, perineural invasion is associated with increased risk of recurrence and metastasis in systematic reviews
Interpretation
Risk Factors Interpretation
Across risk factors for squamous cell carcinoma, exposures that raise tissue damage and immune or local vulnerability stand out, with evidence showing that higher alcohol intake, prior head and neck radiotherapy, and transplant-related immunosuppression are all linked to higher cancer risk, while findings on perineural invasion and scar related tumor development underscore how specific biological pathways also predict recurrence and spread.
07 · Category
Treatment & Practice3 stats
01
Mohs micrographic surgery is associated with lower local recurrence than standard excision for high-risk cutaneous squamous cell carcinoma in comparative studies
02
Surgical excision with appropriate margins is a mainstay treatment for cutaneous squamous cell carcinoma, with cure rates dependent on risk category
03
Definitive radiotherapy is used for patients with unresectable cutaneous squamous cell carcinoma or those who cannot undergo surgery, with outcomes dependent on tumor size and dose
Interpretation
Treatment & Practice Interpretation
In Treatment and Practice, Mohs micrographic surgery shows lower local recurrence than standard excision for high risk cutaneous squamous cell carcinoma, while surgical excision cure rates depend on risk category and definitive radiotherapy is the key option when tumors are unresectable or surgery is not possible with outcomes shaped by tumor size and dose.
08 · Category
Prevention & Screening1 stats
01
Routine skin cancer screening is not universally recommended for the general population in the U.S., but clinician skin exams are commonly performed in practice; the effectiveness depends on risk profile
Interpretation
Prevention & Screening Interpretation
Although routine skin cancer screening is not universally recommended for the general population in the U.S., clinician skin exams are commonly done in practice and their effectiveness hinges on the patient’s risk profile.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Min-ji Park. (2026, February 13). Squamous Cell Carcinoma Statistics. Gitnux. https://gitnux.org/squamous-cell-carcinoma-statistics
MLA
Min-ji Park. "Squamous Cell Carcinoma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/squamous-cell-carcinoma-statistics.
Chicago
Min-ji Park. 2026. "Squamous Cell Carcinoma Statistics." Gitnux. https://gitnux.org/squamous-cell-carcinoma-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+30 additional datasets cited (not shown individually)